Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: A cross-sectional study (Arizona study)

Journal of Dermatology

Volumn 41, Issue 8, 2014, Pages 673-678

  Sanchez Carazo, Jose Luis ^a   Lõpez Estebaranz, Jose Luis ^b   Guisado, Cristina ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c Medical Affairs Department   (Spain)

Author keywords

arthritis; cardiovascular diseases; comorbidities; psoriasis; quality of life

Indexed keywords

ADULT; AGED; ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DERMATOLOGICAL LIFE QUALITY INDEX; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBESITY; PHYSICAL AND MENTAL HEALTH SCORE; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; SLEEP DISORDER; SPAIN; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; HEALTH STATUS INDICATOR; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE;

ADULT; AGED; ARTHRITIS, PSORIATIC; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; OBESITY; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SPAIN;

EID: 84905713316     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12465     Document Type: Article

References (36)

1. Kanai Y, Satoh T, Igawa K, et al,. Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis. Acta Derm Venereol 2012; 92 (4): 367-371. Web of Science
2. National Psoriasis Foundation. Statistics. Available from http://www.psoriasis.org/learn-statistics. Accessed on January 24, 2013.
3. Ferrandiz C, Bordas X, Garcia-Patos V, et al,. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001; 15 (1): 20-23.
4. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-850.
5. Onumah N, Kircik LH,. Psoriasis and its comorbidities. J Drugs Dermatol 2012; 11 (5 Suppl): s5-s10.
6. Wohlrab J, Fiedler G, Gerdes S, et al,. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013; 305 (2): 91-98.
7. Puig-Sanz L,. Psoriasis, a systemic disease? Actas Dermosifiliogr 2007; 98 (6): 396-402.
8. Sommer DM, Jenisch S, Suchan M, et al,. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298 (7): 321-328.
9. Gottlieb AB, Dann F,. Comorbidities in patients with psoriasis. Am J Med 2009; 122 (12): 1150-1159.
10. Lotti T, Hercogova J, Prignano F,. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? Dermatol Ther 2010; 23 (2): 119-122.
11. Myers WA, Gottlieb AB, Mease P,. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24 (5): 438-447.
12. Dauden E, Castaneda S, Suarez C, et al,. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1387-1404.
13. Kimball AB, Guerin A, Tsaneva M, et al,. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011; 25 (2): 157-163.
14. Gelfand JM, Feldman SR, Stern RS, et al,. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51 (5): 704-708.
15. Rapp SR, Feldman SR, Exum ML, et al,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-407.
16. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30 (6): 473-483.
17. Bronsard V, Paul C, Prey S, et al,. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl 2): 17-22.
18. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI) a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19 (3): 210-216.
19. Kumar S, Han J, Li T, et al,. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27: 1293-1298.
20. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167 (15): 1670-1675.
21. Li W, Han J, Qureshi AA,. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis 2012; 71 (8): 1267-1272.
22. Johnston A, Arnadottir S, Gudjonsson JE, et al,. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159 (2): 342-350.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143-3421.
24. Mente A, Yusuf S, Islam S, et al,. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010; 55 (21): 2390-2398.
25. Azfar RS, Gelfand JM,. Psoriasis andmetabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008; 20 (4): 416-422.
26. Love TJ, Qureshi AA, Karlson EW, et al,. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol 2011; 147 (4): 419-424.
27. Gelfand JM, Neimann AL, Shin DB, et al,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296 (14): 1735-1741.
28. Sanchez-Moya AI, Dauden E,. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011; 25 (6): 730-733.
29. Sanchez-Moya AI, Garcia-Doval I, Carretero G, et al,. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain.BIOBADADERM registry. J Eur Acad Dermatol Venereol 2013; 27: 1366-1374.
30. Bordignon V, Bultrini S, Prignano G, et al,. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer. J Biol Regul Homeost Agents 2011; 25 (2): 213-220.
31. Ramagopalan SV, Goldacre R, Skingsley A, et al,. Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Med 2013; 11: 97.
32. Sanchez Carazo JL, Lopez-Estebaranz JL, Guisado C, et al,. Clinical characteristics of patients with moderate to severe psoriasis in Spain. Poster presented at the 40th National Congress of Dermatology and Venereology (AEDV); June 6-9: Oviedo, Spain 2012.
33. Grozdev I, Kast D, Cao L, et al,. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol 2012; 132 (4): 1111-1116.
34. Mattei PL, Corey KC, Kimball AB,. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol 2014; 28 (3): 333-337.
35. Daudén E, Pujol RM, Sánchez-Carazo JL, et al,.; on behalf of the VACAP Study Investigators. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study. Actas Dermosifiliogr. 2013; 104 (9): 807-814.
36. Koo J,. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14 (3): 485-496.